← Eichor
Study identifier: NCT07201922 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Condition: Familial Pulmonary Fibrosis · Interstitial Lung Abnormalities · Interstitial Lung Diseases  ·  Sponsor: Boehringer Ingelheim

PhasePhase 3
Planned participants80
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis. Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo. Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months. Doctors regularly test lung function and take ch…

This description comes directly from the study's public registry record.

Talk to the study team

Boehringer Ingelheim  ·  1-800-243-0127  ·  clintriage.rdg@boehringer-ingelheim.com

Always discuss trial participation with your own doctor first.

Locations (56)

University of California Los AngelesLos Angeles, California, United StatesNot Yet Recruiting
University of Colorado DenverAurora, Colorado, United StatesRecruiting
Clinical Research Specialists LLC - KissimmeeKissimmee, Florida, United StatesRecruiting
University of Kansas Medical CenterKansas City, Kansas, United StatesNot Yet Recruiting
Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting
University of MichiganAnn Arbor, Michigan, United StatesRecruiting
University of MinnesotaMinneapolis, Minnesota, United StatesRecruiting
Weill Cornell Medicine-New York-60569New York, New York, United StatesRecruiting
University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting
Medical University of South CarolinaCharleston, South Carolina, United StatesNot Yet Recruiting
Vanderbilt University Medical CenterNashville, Tennessee, United StatesNot Yet Recruiting
Baylor College of MedicineHouston, Texas, United StatesRecruiting

+ 44 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07201922